Selskabets formål er at drive handel og fabrikation samt hermed beslægtet virksomhed.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 598 mio. | -9.6 mio. | 207.4 mio. | 46.6 mio. | 71 | |
CVR: 51619811
Secondary names: GEMELLI A/S, ELI LILLY EXPORT A/S, Immunitrack A/S
Previous names: ELI LILLY AND COMPANY DENMARK ApS, ELI LILLY DENMARK A/S
Compared to 406 companies in Engroshandel med medicinalvarer og sygeplejeartikler
Comparison is based on industry median values
Companies in the same industry and area
CVR 45224260
CVR 37720089
CVR 45449688
CVR 13902992
CVR 27478700
Sara Dichow Ejlersen joined the board
Lone Rosenørn Jakobsen left the board
Sara Dichow Ejlersen joined as ADM. DIR.
Lone Rosenørn Jakobsen left as ADM. DIR.
The financial health of ELI LILLY DANMARK A/S shows signs of decline, particularly in profitability, with a reported loss of 9.6 million DKK in 2024 following a profit of 16.3 million DKK in 2023. Revenue decreased from 662.6 million DKK in 2023 to 598.0 million DKK in 2024, indicating a downward trend despite a previous increase to 605.6 million DKK in 2022. The company's equity has also decreased from 56.2 million DKK in 2023 to 46.6 million DKK in 2024, raising concerns about its financial stability. Overall, while ELI LILLY DANMARK A/S has a significant presence in the pharmaceutical wholesale industry, its declining margins and equity position suggest challenges ahead.
AI-generated summary
companydata.dk